Literature DB >> 6634274

The hypermobility syndrome.

F Biro, H L Gewanter, J Baum.   

Abstract

The hypermobility syndrome has been recognized as a definitive diagnostic entity among children referred to a Pediatric Arthritis Clinic with musculoskeletal complaints. The diagnosis of hypermobility was made by the ability of the patients to perform at least three of the following maneuvers: (1) extension of the wrists and metacarpal phalanges so that the fingers are parallel to the dorsum of the forearm; (2) passive apposition of thumbs to the flexor aspect of the forearm; (3) hyperextension of elbows (greater than or equal to 10 degrees); (4) hyperextension of knees (greater than or equal to 10 degrees); (5) flexion of trunk with knees extended so palms rest on the floor. Of 262 patients, 15 (5.7%) referred to an arthritis clinic between January 1979 and July 1981 were subsequently determined to have hypermobility as the basis for their rheumatic complaints. Three of these 15 had concomitant juvenile arthritis. The presenting complaint of pain was most often localized to the knees, hands, and fingers. Arthritis and elevated ESRs were not seen except in the three patients who had concomitant juvenile arthritis. All patients responded to physical therapy and nonsteroidal analgesic anti-inflammatory drugs. This is an entity not sufficiently well recognized as a source of musculoskeletal complaints in the United States. It will usually respond well to reassurance and symptomatic therapy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6634274

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  21 in total

1.  Intrarater and Interrater Reliability of the Beighton and Horan Joint Mobility Index.

Authors:  Kyndall L. Boyle; Philip Witt; Cheryl Riegger-Krugh
Journal:  J Athl Train       Date:  2003-12       Impact factor: 2.860

2.  Hypermobility and sports injuries in junior netball players.

Authors:  R Smith; A K Damodaran; S Swaminathan; R Campbell; L Barnsley
Journal:  Br J Sports Med       Date:  2005-09       Impact factor: 13.800

3.  The effects of gender and pubertal status on generalized joint laxity in young athletes.

Authors:  Carmen E Quatman; Kevin R Ford; Gregory D Myer; Mark V Paterno; Timothy E Hewett
Journal:  J Sci Med Sport       Date:  2007-06-26       Impact factor: 4.319

4.  Ligamentous hyperlaxity and dorsal wrist ganglions.

Authors:  Kathleen E McKeon; Daniel A London; Daniel A Osei; Richard H Gelberman; Charles A Goldfarb; Martin I Boyer; Ryan P Calfee
Journal:  J Hand Surg Am       Date:  2013-11       Impact factor: 2.230

5.  PRE- AND POST-OPERATIVE SELF-REPORTED FUNCTION AND QUALITY OF LIFE IN WOMEN WITH AND WITHOUT GENERALIZED JOINT LAXITY UNDERGOING HIP ARTHROSCOPY FOR FEMOROACETABULAR IMPINGEMENT.

Authors:  Mattie Pontiff; Matthew P Ithurburn; Thomas Ellis; Kathleen Cenkus; Stephanie Di Stasi
Journal:  Int J Sports Phys Ther       Date:  2016-06

6.  Evaluation of cardiac functions of patients with benign joint hypermobility syndrome.

Authors:  Sevket Balli; Mehmet Zafer Aydın; Vedat Gerdan; Ibrahim Ece; Mehmet Burhan Oflaz; Ayse Esin Kibar; Eylem Sen Dalkiran
Journal:  Pediatr Cardiol       Date:  2013-09-08       Impact factor: 1.655

7.  Lax ligament syndrome in children associated with blue sclera and bat ears.

Authors:  F M Howard
Journal:  Br J Gen Pract       Date:  1990-06       Impact factor: 5.386

8.  General joint hypermobility and temporomandibular joint derangement in adolescents.

Authors:  L Westling; A Mattiasson
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

9.  Incidence of joint hypermobility syndrome in a military population: impact of gender and race.

Authors:  Danielle L Scher; Brett D Owens; Rodney X Sturdivant; Jennifer Moriatis Wolf
Journal:  Clin Orthop Relat Res       Date:  2010-07       Impact factor: 4.176

10.  Is the benign joint hypermobility syndrome benign?

Authors:  H A el-Shahaly; A K el-Sherif
Journal:  Clin Rheumatol       Date:  1991-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.